ライフサイエンスコーパス: leiomyosarcoma

1 outcomes for patients with primary vascular leiomyosarcoma.

2 ic therapies did not impact LR, DM, or OS of leiomyosarcoma.

3 s received a confirmed diagnosis of vascular leiomyosarcoma.

4 posarcoma, dedifferentiated liposarcoma, and leiomyosarcoma.

5 ent age was 54.0 (21-77 years); 42 (34%) had leiomyosarcoma.

6 or second-line therapy for advanced uterine leiomyosarcoma.

7 or second-line therapy for advanced uterine leiomyosarcoma.

8 vulva, and 1 multiple Epstein-Barr virus(+) leiomyosarcoma.

9 re malignant transformation of UL to uterine leiomyosarcoma.

10 d favorable results in patients with uterine leiomyosarcoma.

11 at included 26 primary specimens of vascular leiomyosarcoma.

12 were found in gastrointestinal leiomyomas or leiomyosarcomas.

13 ohistochemically from typical leiomyomas and leiomyosarcomas.

14 tant bands were found in 3 leiomyomas and 11 leiomyosarcomas.

15 here were no mutations in 3 leiomyomas and 4 leiomyosarcomas.

16 scle and a series of primary retroperitoneal leiomyosarcomas.

17 s of the skin, anal carcinoma, and pediatric leiomyosarcomas.

18 inferior vena cava and account for 5% of all leiomyosarcomas.

19 rm of chromosome 1, clustered with malignant leiomyosarcomas.

20 upregulation of downstream effectors in most leiomyosarcomas.

21 ression are up-regulated in high-grade human leiomyosarcomas.

22 omas, carcinosarcomas, stromal sarcomas, and leiomyosarcomas.

23 ntestinal stromal tumors or gastrointestinal leiomyosarcomas.

24 responses were noted in 17 patients with GI leiomyosarcomas.

25 omosomes 15, 18, 21, and X was infrequent in leiomyosarcomas (1 of 6 tumors for each chromosome) and

26 lymphoblastic leukemia, 1 Hodgkin disease, 8 leiomyosarcoma, 1 hepatoblastoma, and 1 schwannoma.

27 ell tumors, 2 of 3 synovial sarcomas, 4 of 4 leiomyosarcomas, 1 of 1 malignant fibrous histiocytoma,

28 revalent histologies were liposarcoma (50%), leiomyosarcoma (26%), and malignant fibrous histiocytoma

29 Four of 10 patients with non-GI leiomyosarcomas achieved a partial response.

30 d stage I, II, III, or IV high-grade uterine leiomyosarcoma, adjuvant treatment with gemcitabine-doce

31 ine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline

32 n patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior ch

33 hour trabectedin regimen in liposarcomas and leiomyosarcomas, although the qwk 3-hour regimen also de

34 Leiomyosarcoma and angiosarcoma may occur disproportiona

35 lished treatment option for advanced uterine leiomyosarcoma and has demonstrated efficacy in nonleiom

36 ent-naive patient who has metastatic uterine leiomyosarcoma and has experienced complete tumor remiss

37 ase at presentation, the histologic subtypes leiomyosarcoma and malignant peripheral-nerve tumor, mic

38 We examined archival materials from 16 leiomyosarcomas and 13 benign leiomyomas by polymerase c

39 patients with STS (17 gastrointestinal [GI] leiomyosarcomas and 39 other histologies) were treated o

40 tudied, LOH on chromosome 10 was frequent in leiomyosarcomas and absent in benign leiomyomas.

41 ly regulated in selected human tumors (e.g., leiomyosarcomas and colorectal cancer) by methylation of

42 ellite instability was found infrequently in leiomyosarcomas and not detected in leiomyoma.

43 ymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusively in GISTs (21%)

44 n prostate cancer, liver cancer, soft tissue leiomyosarcoma, and glioblastoma multiforme.

45 ignancies, including fibrosarcoma, leukemia, leiomyosarcoma, and myxosarcoma, which are unusual in p5

46 location, recurrent disease at presentation, leiomyosarcoma, and nonliposarcoma histology were indepe

47 sted of scrotal wall liposarcoma, epididymal leiomyosarcoma, and recurrent spindle cell malignancy of

48 ients, one with cholangiocarcinoma, one with leiomyosarcoma, and three with non-small-cell lung cance

49 ms' tumors, rhabdomyosarcomas, liposarcomas, leiomyosarcomas, and adrenal cortical carcinomas.

50 grade undifferentiated pleomorphic sarcomas, leiomyosarcomas, and carcinosarcomas that widely recapit

51 Leiomyosarcomas appear causatively linked to EBV, wherea

52 Vascular leiomyosarcomas are a rare subtype of leiomyosarcomas th

53 Vascular leiomyosarcomas are aggressive malignant tumors, with hi

54 Here, we have chosen leiomyosarcoma as a model for examining the relationship

55 alignant tumors derived from the myometrium (leiomyosarcomas), (b) is overexpressed in tumor-associat

56 hways, we analyzed the expression profile of leiomyosarcomas by DNA microarray analysis.

57 lung cancer, skin cancer, germ cell tumors, leiomyosarcomas, cancers of the head and neck, conjuncti

58 nal AGS protein (AGS4) from a human prostate leiomyosarcoma cDNA library.

59 show that HGF/SF-Met signalling in the human leiomyosarcoma cell line SK-LMS-1 enhances its in vivo t

60 tive form of Stat3, Stat3beta into the human leiomyosarcoma cell line SK-LMS-1.

61 f conditioned medium from the SK-LMS-1 human leiomyosarcoma cell line.

62 n of ITGA7 expression in prostate cancer and leiomyosarcoma cell lines suppressed tumor growth and ce

63 , U373 and SNB19), as well as SK-LMS-1 human leiomyosarcoma cells are also sensitive to fM-GAi; (2) f

64 Ectopic overexpression of TIMP-3 in cultured leiomyosarcoma cells conferred an epithelial morphology,

65 In experiments with human SK-LMS-1 leiomyosarcoma cells, we show that the Akt kinase is act

66 In contrast, the monthly death rate after leiomyosarcoma diagnosis increased from 5% in the first

67 emic myocardium, human heart, and a prostate leiomyosarcoma for entities that activated G protein sig

68 d there is loss of the wild-type allele in a leiomyosarcoma from the proband.

69 Distinction of malignant uterine leiomyosarcomas from benign leiomyomas by morphological

70 pathway in smooth muscle transformation and leiomyosarcoma genesis, and support treatment of selecte

71 nt and quantitative method for assessment of leiomyosarcoma grade and mitotic activity thereby render

72 oma, lipoma, gastrointestinal stromal tumor, leiomyosarcoma, granular cell tumor).

73 Interestingly, 8 of 14 (57.2%) informative leiomyosarcomas had LOH for at least one marker on chrom

74 several human diseases, notably soft tissue leiomyosarcoma, hepatocellular carcinoma, and hematologi

75 tumors (HR, 1.60; 95% CI, 1.03 to 2.49) and leiomyosarcoma (HR, 2.67; 95% CI, 1.22 to 5.85) but not

76 kemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.

77 dentified in association with an outbreak of leiomyosarcoma in the swim bladders of Atlantic salmon.

78 detected in the tumor cells in 85 and 88% of leiomyosarcomas in HIV-infected people and transplant re

79 Uterine leiomyosarcoma is the most common subtype of uterine sar

80 After NHL, leiomyosarcoma is the second leading cancer in children

81 letely resected, uterine-limited, high-grade leiomyosarcoma is under investigation.

82 human sarcoma cells, including fibrosarcoma, leiomyosarcoma, liposarcoma, synovial sarcoma, and neuro

83 advances in the diagnosis of the more common leiomyosarcoma (LMS) anatomic variants, potentially usef

84 Leiomyosarcoma (LMS) is a mesenchymal cancer that occurs

85 Leiomyosarcoma (LMS) is a soft tissue tumor with a signi

86 Leiomyosarcoma (LMS) is a tumor of smooth muscle that ca

87 Leiomyosarcoma (LMS) is one of the most common subtypes

88 Uterine leiomyosarcoma (LMS) is staged by the modified Internati

89 Management of uterine sarcomas including leiomyosarcoma (LMS), endometrial stromal sarcoma, high-

90 mal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation.

91 Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progress

92 tients with recurrent and metastatic uterine leiomyosarcoma (LMS).

93 ates with poor prognosis in nongynecological leiomyosarcoma (LMS).

94 vestigations impacting management of uterine leiomyosarcoma (LMS).

95 remains in the differentiation of GIST from leiomyosarcomas (LMSs).

96 In contrast to leiomyosarcomas, LOH for chromosome 10 was not found in

97 histopathologies: fibrosarcoma, liposarcoma, leiomyosarcoma, malignant fibrous histiocytoma, or synov

98 diagnoses were myxofibrosarcoma (n = 22) and leiomyosarcoma (n = 20).

99 No patients with leiomyosarcoma (n=10) had an objective response.

100 Leiomyosarcomas (n = 101) were the most frequently repor

101 ing (n = 13), one fibrosarcoma (n = 12), six leiomyosarcomas (n = 29), seven liposarcomas (n = 31), t

102 ll as a few tumors of a second type (uterine leiomyosarcoma) not previously associated with this tran

103 We report a case of primary low-grade leiomyosarcoma of the mandible in an otherwise healthy y

104 t (four malignant fibrous histiocytomas, two leiomyosarcomas, one pleomorphic rhabdomyosarcoma, one d

105 enetic or molecular genetic abnormalities in leiomyosarcomas or leiomyomas and surveyed chromosomes 7

106 Eleven children (17%) had leiomyosarcomas (or leiomyomas), which are otherwise exc

107 d in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant

108 activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatri

109 e the role of aberrant PI3K-AKT signaling in leiomyosarcoma pathogenesis, we genetically inactivated

110 a pleomorphic mesenchymal tumor, probably a leiomyosarcoma, rather than an epithelial tumor.

111 was identified in Oncopig STS cell lines and leiomyosarcomas, respectively.

112 tutive mTOR activation was restricted to the leiomyosarcomas, revealing the requirement for additiona

113 Leiomyosarcoma risk was significantly increased for surv

114 ncopig STS cell line (fibroblast) and tumor (leiomyosarcoma) RNA-seq data to compare Oncopig and huma

115 patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overa

116 Treatment of well-established leiomyosarcoma SKLMS-1 and rhabdomyosarcoma RD xenograft

117 Restoration of wt p53 expression in human leiomyosarcoma SKLMS-1 cells that contain mutant p53 mar

118 This established the diagnosis of leiomyosarcoma; subsequently, an en bloc resection of ma

119 cancer, squamous cell cancer, lymphoma, and leiomyosarcoma, suggesting that the decreased expression

120 scular leiomyosarcomas are a rare subtype of leiomyosarcomas that most commonly affect the inferior v

121 These results suggest, that for leiomyosarcoma, the degree of fatty acyl unsaturation ma

122 Leiomyosarcomas typically have complex cytogenetic abnor

123 r cells, including the lines SK-LMS-1 (human leiomyosarcoma), U118 (human glioblastoma), and DU145 (h

124 Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy w

125 ive response in 35% of patients with uterine leiomyosarcoma (uLMS).

126 ghly aggressive and pleomorphic tumors named leiomyosarcomas (ULMS).

127 months (range, 1 day to 89 months) and after leiomyosarcoma was 12 months (range, 10 days to 19 month

128 Development of leiomyosarcoma was significantly more common after AA pl

129 Liposarcoma and leiomyosarcoma were associated with late recurrence and

130 Leiomyosarcomas were reported with two age peaks, in chi

131 all female animals developed massive uterine leiomyosarcomas, whereas practically all males exhibited

132 -grade or high-grade advanced liposarcoma or leiomyosarcoma who had received at least two previous sy

133 tinguish gastrointestinal stromal tumor from leiomyosarcoma with high sensitivity and specificity.

134 smooth muscle cell hyperplasia and abdominal leiomyosarcomas, with a very rapid onset and elevated in